Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Generic medicines

Pfizer gains UK interim injunction against Sandoz and LloydsPharmacy over Lyrica

Sandoz challenged by Pfizer in Patents Court to prevent it from supplying pregabalin for treatment of neuropathic pain.

Warner-Lambert – a subsidiary of Pfizer (logo pictured) – has been awarded an UK interim injunction preventing Sandoz from selling or supplying a generic version of Lyrica (pregabalin)

Source: 360b / Shutterstock.com

Pfizer has obtained an interim injunction preventing Sandoz from supplying a full-label generic version of Lyrica (pregabalin)

Warner-Lambert – a subsidiary of Pfizer – has been awarded an UK interim injunction preventing Sandoz from selling or supplying a generic version of Lyrica (pregabalin). 

Pfizer has also announced that it has been given the go-ahead to appeal against the ruling made in the High Court in September 2015, when the company lost the secondary use patent protection for Lyrica for the treatment of neuropathic pain. 

Warner-Lambert went to the Patents Court in London on 4 November 2015 to challenge the decision by the generic manufacturer Sandoz to sell and supply pregabalin as a ‘full-label’ generic product for the treatment of neuropathic pain, generalised anxiety and epilepsy, and the decision by LloydsPharmacy to dispense it. 

Under the terms of the ruling, LloydsPharmacy was also prevented from dispensing the product in its possession. 

The case is the latest move in an ongoing battle by Pfizer to protect its secondary use patent of Lyrica for the treatment of neuropathic pain, which runs out in 2017.  

The Patents Court case focuses on the decision by Sandoz to launch a full-label generic pregabalin product. 

In a statement, Pfizer says its decision to involve LloydsPharmacy in the litigation was not taken lightly. “This was our last resort and followed many attempts to reach an amicable resolution outside of the courtroom,” it says. “We had hoped to be able to reach agreement with LloydsPharmacy that they would cease dispensing ‘Pregabalin Sandoz’ which, with a full label, is indicated for neuropathic pain.” 

LloydsPharmacy confirmed that Pfizer is taking action against the company in a case involving the supply of a full-label product but made no other comment. 

In a statement, Sandoz confirmed that it had marketing authorisation for both full and ‘skinny’ label products for Pregabalin Sandoz. A skinny label excludes certain indications that are protected by patents.

It began supplying the full-label product — indicated for neuropathic pain, epilepsy and general anxiety disorder — in October 2015. The skinny label product is indicated for epilepsy and generalised anxiety disorder and has been available since June 2015.

“Pfizer initiated legal proceedings against Sandoz in respect of a supply of a full-label product,” says Sandoz. “Pending full trial of its claims, Pfizer has obtained an interim injunction preventing Sandoz from supplying or offering to supply the full-label product. Sandoz cannot comment further on the ongoing litigation. Recent legal developments do not affect the supply and dispensing of its skinny label product.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200121

Readers' comments (1)

  • Patti

    I have taken this drug for years at the very high price of up to 300 dollars a month. It is way past time to get this in generic form. I have taken it for better than 10 yrs now for fibro. It is the most expensive drug in my army of meds for more than one medical condition. There are times when I can't take all the doses I should a day due to the cost. PLEASE get this drug generic ASAP!!!!

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Warner-Lambert – a subsidiary of Pfizer (logo pictured) – has been awarded an UK interim injunction preventing Sandoz from selling or supplying a generic version of Lyrica (pregabalin)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.